FMS TECHNOLOGY

History

FMS member John F. Currie Ph.D. developed FMS’s core technology, in conjunction with research grants from the U.S. Defense Advanced Research Projects Agency (DARPA), well in advance of a recent flurry of activity in the noninvasive medical diagnostics arena. Doctor Currie developed a prototype minimally intrusive polymer-based flexible transdermal electrochemical sensor for remote medical diagnostics. 

 

Competition

Presently, there are numerous in vitro diagnostic testing devices which rely on extracting a bodily fluid sample from the patient and then transferring that sample to a separate testing device. There are far fewer devices that test in vivo.  There are vanishingly few that are not invasive yet provide continuous monitoring.  To be sure, there are other noninvasive and minimally invasive approaches (ocular scanning, photoacoustics, etc.) but our transdermal sampling is unique.  Inter alia, it does not rely on any proxy: it physically assays the fluids in question.

 

Intellectual Property

FMS has filed two world patent applications (PCT) relating to the core technology and its commercial embodiments. Our technology and methods are proprietary and designed within the claims of the pending patent applications.  We plan to further expand FMS's patent estate.